EPMC Pharma - Av. Louise 523

About EPMC Pharma

One Europe for our clients

Europe is key to the global success of any pharmaceutical company.  A region that is a leader in research and technology and also the world’s wealthiest economy is increasingly seen as a gateway to international approval.  Success in Europe opens the door to a region that places access to innovative health care as a priority for its citizens, and offers the credibility of passing the approval of one of the world’s most rigorous authorities.

Increasingly regulation of the pharmaceutical market occurs at European level, and companies are obliged to maintain an understanding of the latest European legislation.  However, there are many areas, such as the design of clinical trials, where European Member states continue to advance their own agendas.

EPMC helps clients to work above this complexity: taking charge of both European level applications and local administration, so that they can focus on the business of developing new and effective treatments and bringing them onto the European market as fast as possible.

A mission, based on experience

EPMC Pharma, a private company based in Brussels (Belgium), was founded in 2008 by Jean-Pierre Osselaere with a mission to help pharmaceutical companies register and market innovative new medicines at the European Level without unnecessary delay.  Before creating EPMC Pharma, Jean-Pierre worked for 26 years for Schering-Plough where exercised several senior management positions before retiring as Vice President, Global Regulatory Affairs, Europe.

Following Jean-Pierre’s death in 2010 the management of EPMC has passed to the other founding partners, Jacques De Waele and Anne Soetemont who, together with and an associated team of experts are as committed as ever to the mission of facilitating access for innovative pharmaceuticals to the European Market.

EPMC: expertise and entrepreneurialism

We believe in what we do, to the extent that we develop and market our own products: an example being ‘Sucrose 24%’, an aqueous sterile oral solution used in the treatment of neonatal pain.

EPMC is at home in the heart of Europe.  From our office in Brussels we support a wide variety of pharmaceutical and biotech companies, from multi-nationals to start-ups, helping them to efficiently bring their products to market.